Comorbidities in Psoriatic Arthritis: A Narrative Review

• Published in: Clinical therapeutics 2023-02, Vol.45 (2), p.177-189
• Main Authors: Panagiotopoulos, Alexandros, Fragoulis, George E.
• Format: Article
• Language: English
• Subjects: Anxiety; Arthritis; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - epidemiology; Atherosclerosis; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Cardiovascular Diseases - therapy; Clinical trials; Cohort analysis; comorbidities; Comorbidity; Disorders; Health services; Humans; Hypertension; Inflammation; Literature reviews; Mental depression; Mental Disorders; Mental health; mental health disorders; Meta-analysis; Metabolic disorders; Metabolic syndrome; Mortality; Obesity; Patients; Psoriasis; Psoriatic arthritis; Rheumatology; Risk factors; Systematic review; TNF inhibitors; Tumor necrosis factor-TNF; Weight control
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2023.01.006

Psoriatic arthritis (PsA) is a common type of inflammatory arthritis. Patients with PsA present with certain extra-articular manifestations and comorbidities (often collectively called psoriatic disease). The purpose of the present review was to highlight the main comorbidities in the setting of PsA. A narrative review was performed using data from articles found in a search of PubMed and Scopus using the terms psoriatic arthritis and comorbidities. Cardiovascular disease (CVD), as well as metabolic and mental health disorders, are the most common comorbidities in patients with PsA. In most cases, underlying inflammation seems to be involved in the increased risk for CVD in PsA, while a bidirectional relationship seems to operate between mental health disorders and psoriatic disease. The treatment of patients with PsA, especially with biologic disease-modifying antirheumatic drugs, has been shown to lead to favorable outcomes regarding the CVD risk. However, it is debatable whether specific drug classes are more effective than others or should be avoided in patients with CVD risk factors. Comorbidity of mental health disorders is even more complex, given the difficulties in measuring and reporting these comorbidities in clinical trials and in clinical practice. Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA. The education of clinicians, health care professionals in rheumatology, and patients could be useful in achieving this goal.